AAminove
Back to library

IGF-1 LR3

Animal / preclinicalWADA prohibited

Also known as: Long R3 IGF-1

Growth-hormone secretagoguesMuscle growth (claimed)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A modified, long-acting form of insulin-like growth factor 1 used in bodybuilding. Carries real risks (hypoglycaemia, tissue growth) and is WADA-prohibited.

Mechanism

Activates IGF-1 receptors driving cell growth; the LR3 modification extends half-life and reduces binding-protein inactivation.

Evidence

Animal / preclinicalWhat does this mean?

No human efficacy trials for physique use; meaningful safety concerns including hypoglycaemia.

Community-reported information

Community reports vary. Anecdotal, unvalidated and potentially dangerous; general information only.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~20–30 hours (LR3 variant).

Storage

Refrigerate; sensitive to degradation.

Commonly reported side effects

  • Hypoglycaemia
  • Localised tissue growth
  • Headache

Legal status by region

  • USNot FDA-approved for human use.
  • AUPrescription-only; import controlled.

Legal status changes over time; verify locally before relying on this.

Citations